Mon, Jun 2, 2025
Sae Pol1 
, Pooja Shah2 , Vaishali Gaikwad3 , Sujata Dharmshale4 , Mansi Rajmane5 , Rajesh Karyakarte6
, Pooja Shah2 , Vaishali Gaikwad3 , Sujata Dharmshale4 , Mansi Rajmane5 , Rajesh Karyakarte6
1- Department of Microbiology, BJ GMC Pune, India
2- Department of Microbiology, BJ GMC Pune- India
3- Department of Microbiology, GMC Satara- India
4- Department of Microbiology, GMC Baramati- India
5- Department of Microbiology, BJ GMC Pune-India
6- Department of Microbiology, BJ GMC Pune- India ,karyakarte@hotmail.com
2- Department of Microbiology, BJ GMC Pune- India
3- Department of Microbiology, GMC Satara- India
4- Department of Microbiology, GMC Baramati- India
5- Department of Microbiology, BJ GMC Pune-India
6- Department of Microbiology, BJ GMC Pune- India ,
Abstract: (589 Views)
Background-COVID-19 pandemic started in March 2020 and though cases are reported till now, major cases were seen till January 2022. During this pandemic,the whole healthcare system was diverted into COVID-19 patient care. Both Tuberculosis (TB) and COVID-19 are diseases of respiratorysystem, and it is important to study impact of COVID-19 on Tuberculosis. The main objective of study is- To detect the M.tuberculosis and rifampicin resistance before, during and after COVID-19 restrictions were fully released.
Material and methods- Pulmonary and extra pulmonary samplesfrom 1st January 2018 till 31st December 2022(five years) were included in the present study. The period was divided as-
2018,2019 – BeforeCOVID-19
2020,2021 –COVID-19 period with restrictions (such as use of masks, social distancing, avoiding gatherings)
2022 –COVID-19 period without restrictions.
All samples received in Tuberculosis section were subjected to CBNAAT. Samples were processed according to manufacturer’s guidelines.
Results- There was no significant difference in samples received per year from 2018-2022. The positivity of M.tuberculosis decreased from 22.52%in pre-COVID-19 period to 15.70% in COVID-19 period with restrictions and increased again in 2022(16.80%). Rifampicin resistance was also decreased from10.40% to 6.89% in COVID-19 period with restrictions. Decrease in positivity was not observed in Extrapulmonary tuberculosis cases.
Conclusion –Restrictionsimposed during COVID-19 period could decrease Tuberculosis as well as rifampicin resistance. Thus implication of restrictions for TB suspected and positive patients on regular basis can help in preventing spread of the disease.
Material and methods- Pulmonary and extra pulmonary samplesfrom 1st January 2018 till 31st December 2022(five years) were included in the present study. The period was divided as-
2018,2019 – BeforeCOVID-19
2020,2021 –COVID-19 period with restrictions (such as use of masks, social distancing, avoiding gatherings)
2022 –COVID-19 period without restrictions.
All samples received in Tuberculosis section were subjected to CBNAAT. Samples were processed according to manufacturer’s guidelines.
Results- There was no significant difference in samples received per year from 2018-2022. The positivity of M.tuberculosis decreased from 22.52%in pre-COVID-19 period to 15.70% in COVID-19 period with restrictions and increased again in 2022(16.80%). Rifampicin resistance was also decreased from10.40% to 6.89% in COVID-19 period with restrictions. Decrease in positivity was not observed in Extrapulmonary tuberculosis cases.
Conclusion –Restrictionsimposed during COVID-19 period could decrease Tuberculosis as well as rifampicin resistance. Thus implication of restrictions for TB suspected and positive patients on regular basis can help in preventing spread of the disease.
Research Article: Original Paper |
Subject:
Microbiology
Received: 2024/07/24 | Accepted: 2024/12/31
Received: 2024/07/24 | Accepted: 2024/12/31
References
1. Sathiyamoorthy R, Kalaivani M, Aggarwal P, Gupta SK. Prevalence of pulmonary tuberculosis in India:A systematic review and meta-analysis. Lung India. 2020; 37: 45-52. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. World Health Organisation. Global Tuberculosis Control Report 2011. . 2011. [View at Publisher]
3. Press Information Bureau Government of India Ministry of Health and Family Welfare. India records more than 82,000 Recoveries for two days in a row. 2021. [View at Publisher]
4. Agarwala P, Bhargava A, Gahwai DK, Negi SS, Shukla P, Dayama S. Epidemiological Characteristics of the COVID-19 Pandemic During the First and Second Waves in Chhattisgarh, Central India: A Comparative Analysis. Cureus. 2022; 14(4):e24131. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. J Med Virol.2021; 93(1): 194-196. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Zheng Z, Peng F, Xu B. Risk factors of critical & mortal COVID‐19 cases: a systematic literature review and meta‐analysis. J Infect. 2020; 10. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Luke E, Swafford K, Shirazi G, Venketaraman V. TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection. Front Biosci (Schol Ed). 2022; 14(1): 6. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Rai B, Shukla A, Dwivedi L K. Dynamics of COVID-19 in India: A review of different phases of lockdown. Population Medicine. 2020; 2(July): 21. [View at Publisher] [DOI] [Google Scholar]
9. Wikipedia. Covid-19 lockdown in India. 2023. [View at Publisher]
10. Hopewell PC, Reichman LB, Castro KG. Parallels and Mutual Lessons in Tuberculosis and COVID-19 Transmission, Prevention, and Control. Emerg Infect Dis. 2021; 27(3): 681-686. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Asadi S, Cappa CD, Barreda S, Wexler AS, Bouvier NM, Ristenpart WD. Efficacy of masks and face coverings in controlling outward aerosol particle emission from expiratory activities. Sci Rep. 2020; 10: 15665.
https://doi.org/10.1038/s41598-020-72798-7 [View at Publisher] [DOI] [PMID] [Google Scholar]
12. the times of india. Devastating 2nd wave, billion+ vaccination: 12 charts show how india fought covid in 2021. 2022. [View at Publisher]
13. Migliori GB, Thong PM, Alffenaar J-W. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. EurRespir J. 2021; 58: 2101786. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Trajman A, Felker I, Alves LC, Coutinho I, Osman N, Meehan SA, et al. The COVID-19 and TB syndemic: The way forward. International J of Tuberculosis and lung disease. 2022; 26(8): 710-719. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.